BNT-325 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BNT-325’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BNT-325 overview
BNT-325 (DB-1305) is under development for the treatment of solid tumor, esophageal cancer, pancreatic cancer, malignant mesothelioma, castration-resistant prostate cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), non-small cell lung cancer, triple-negative breast cancer (TNBC), colorectal cancer, ovarian cancer, duodenal cancer, gastric cancer, adenocarcinoma of the gastroesophageal junction, platinum-resistant ovarian epithelial cancer, endometrial cancer, cervical cancer, primary peritoneal cancer, fallopian tube cancer. It is humanized anti-TROP2 IgG1 mAb with a cytotoxic payload targeting topisomerase I. The drug candidate is administered through intravenous route as injection. . It is being developed based on Duality Immune Toxin Antibody Conjugates (“DITAC”) platform.
It was also under development for small-cell lung cancer.
Duality Biologics (Shanghai) overview
Duality Biologics (Shanghai) is a company focusing on the development, commercialization and discovery of new modality biologics to provide solutions. The company is headquartered in Shanghai, China.
For a complete picture of BNT-325’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
